7-硝基吲哚-2-甲酸乙酯 | 6960-46-9

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 7-硝基吲哚-2-甲酸乙酯
• 中文别名: 7-硝基吲哚-2-羧酸乙酯
• 英文名称: ethyl 7-nitroindole-2-carboxylate
• 英文别名: ethyl 7-nitro-1H-indole-2-carboxylate
• CAS: 6960-46-9
• 化学式: C₁₁H₁₀N₂O₄
• mdl: MFCD00216475
• 分子量: 234.211
• InChiKey: GTZAIVBXGPLYGD-UHFFFAOYSA-N

物化性质

• 熔点：
  90-96 °C
• 沸点：
  376.52°C (rough estimate)
• 密度：
  1.3240 (rough estimate)
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与不相容的材料以及光照接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  87.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 安全说明：
  S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	Ethyl 7-nitroindole-2-carboxylate 95+% Material Safety Data Sheet
Synonym:	None
CAS:	6960-46-9

Section 1 - Chemical Product MSDS Name:Ethyl 7-nitroindole-2-carboxylate 95+% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6960-46-9	Ethyl 7-nitroindole-2-carboxylate	95+	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6960-46-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 90.00 - 92.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: negligible
Specific Gravity/Density: Not available.
Molecular Formula: C11H10N2O4
Molecular Weight: 234.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6960-46-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 7-nitroindole-2-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 6960-46-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6960-46-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6960-46-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-硝基吲哚-2-甲酸乙酯 在 一水合肼 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 5.0h， 生成 5-(7-nitro-1H-indol-2-yl)-1,3,4-oxadiazole-2-thiol
  参考文献：
  名称：

  Narayana; Ashalatha; Vijaya Raj, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2009, vol. 48, # 12, p. 1794 - 1805

  摘要：

  DOI：
• 作为产物：
  描述：

  (E)-ethyl pyruvate 2-(2-nitrophenyl)hydrazone 在 PPA 作用下， 反应 0.5h， 以78%的产率得到7-硝基吲哚-2-甲酸乙酯
  参考文献：
  名称：

  Fischer Indolization of Variously ortho-Substituted Phenylhydrazones. Fischer Indolization and Its Related Compounds. XXV.

  摘要：

  各种丙酮酸乙酯 2-（2-取代苯基）酰肼（1）在酸催化剂作用下进行费歇尔吲哚化反应。所有的苯肼都得到了相应的 7-取代吲哚（2）。此外，如果苯肼的正位取代基是电子疏导型的，或者其中心原子上有一个未共享的电子对，则往往会产生 4 或 5 取代的吲哚（3），这是由正位取代基在环化过程中发生迁移而产生的；而如果苯肼的正位取代基是电子吸引型的，则往往很少或根本不会产生这种异常产物。所使用的酸催化剂对产物的产率有一定影响，但对产物的种类没有影响。

  DOI：

  10.1248/cpb.41.1910

文献信息

• Indole compound
  申请人：Yasuma Tsuneo

  公开号：US20080096877A1

  公开（公告）日：2008-04-24

  The purpose of the present invention is to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein R 1 is a hydrogen atom or a halogen atom; R 2 is a group represented by wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.

  本发明的目的是提供一种作为药物剂如用于预防或治疗糖尿病、肥胖等的葡萄糖激酶激活剂有用的葡萄糖激酶激活剂。 本发明提供了一种包含由公式（I）表示的化合物的葡萄糖激酶激活剂： 其中 R1 是氢原子或卤素原子； R2 是由表示的组 其中每个符号在说明书中定义，或其盐或前药。
• N-酰基磺酰胺类FBPase抑制剂、其制备方法、 药物组合物及用途
  申请人：中国医学科学院药物研究所

  公开号：CN107098846B

  公开（公告）日：2020-10-09

  本发明公开了新结构的N‑酰基磺酰胺类FBPase抑制剂、及其制法和药物组合物与用途。具体而言，本发明涉及通式I所示的N‑酰基磺酰胺类FBPase抑制剂，其可药用盐，及其制备方法，含有一个或多个该类化合物的组合物，和该类化合物在制备FBPase抑制剂或治疗FBPase有关的疾病药物中的用途，及在制备预防和/或治疗糖尿病药物中的用途。
• Indoles via Knoevenagel–Hemetsberger reaction sequence
  作者：William L. Heaner IV、Carol S. Gelbaum、Leslie Gelbaum、Pamela Pollet、Kent W. Richman、William DuBay、Jeffrey D. Butler、Gregory Wells、Charles L. Liotta

  DOI：10.1039/c3ra42296h

  日期：——

  sequential reaction of aromatic aldehydes with ethyl azidoacetate in the presence of sodium ethoxide to form the corresponding ethyl α-azido-β-arylacrylates (Knoevenagel process) followed by a solvent mediated thermolysis (Hemetsberger process). The isolated yields of the ethyl α-azido-β-arylacrylates were significantly increased when employing the sacrificial electrophile ethyl trifluoroacetate. 1H NMR and

  通过芳族醛与环戊烯的顺序反应合成了一系列取代的吲哚 叠氮基乙酸乙酯 在......的存在下 乙醇钠形成相应的乙基α-叠氮基-β-芳基丙烯酸乙酯（Knoevenagel法），然后进行溶剂介导的热分解（Hemetsberger法）。使用牺牲亲电试剂时，α-叠氮基-β-芳基丙烯酸乙酯的分离收率显着提高三氟乙酸乙酯。对α-叠氮基-β-芳基丙烯酸乙酯的1 H NMR和1 H- 13 C NMR耦合分析表明，该缩合反应具有立体特异性，只能检测到Z异构体。溶剂介导的间位取代的乙基α-叠氮基-β-芳基丙烯酸酯的热处理导致5位和7位取代的吲哚的形成，其中5位区域异构体比7位区域异构体略受青睐。（2 Z，2 Z '）-二乙基3,3'-（1,3-亚苯基）双（2-叠氮基丙烯酸酯）和（2 Z，2 Z '）-二乙基3,3'-（1的相似热处理，4-亚苯基）双（2-叠氮基丙烯酸酯）专门生产吡咯并吲哚，1,5-二氢吡咯并[2
• INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS
  申请人：Kim Soon Ha

  公开号：US20100210647A1

  公开（公告）日：2010-08-19

  The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient.

  本发明涉及新的吲哚化合物，其药学上可接受的盐或异构体，用于预防或治疗细胞坏死和坏死相关疾病。本发明还涉及一种预防或治疗细胞坏死和坏死相关疾病的方法和组合物，该组合物包括所述吲哚化合物作为活性成分。
• Combination therapy
  申请人：——

  公开号：US20040102360A1

  公开（公告）日：2004-05-27

  The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors or a compound which is an inhibitor of Akt and an inhibitor of a protein kinase, which methods comprise administering to a mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound(s) which are inhibitors of Akt and compound(s) which are inhibitors of protein kinases. The invention also relates to methods of preparing such compositions.

  本发明涉及使用至少两种Akt抑制剂的组合或一种同时是Akt抑制剂和蛋白激酶抑制剂的化合物来治疗癌症的方法，该方法包括向哺乳动物施用来自以下组合中选择的至少两种治疗剂的量，该组合包括Akt抑制剂和蛋白激酶抑制剂。该发明还涉及制备这种组合物的方法。

表征谱图